# A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT

> **NCT00232635** · PHASE2 · COMPLETED · sponsor: **Arrow Therapeutics** · enrollment: 27 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** A-60444

## Key facts

- **NCT ID:** NCT00232635
- **Lead sponsor:** Arrow Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2010-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00232635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00232635, "A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00232635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*